These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
179 related articles for article (PubMed ID: 33171278)
1. Plasma levels of apelin are reduced in patients with liver fibrosis and cirrhosis but are not correlated with circulating levels of bone morphogenetic protein 9 and 10. Owen NE; Nyimanu D; Kuc RE; Upton PD; Morrell NW; Alexander GJ; Maguire JJ; Davenport AP Peptides; 2021 Feb; 136():170440. PubMed ID: 33171278 [TBL] [Abstract][Full Text] [Related]
2. Reduced circulating BMP10 and BMP9 and elevated endoglin are associated with disease severity, decompensation and pulmonary vascular syndromes in patients with cirrhosis. Owen NE; Alexander GJ; Sen S; Bunclark K; Polwarth G; Pepke-Zaba J; Davenport AP; Morrell NW; Upton PD EBioMedicine; 2020 Jun; 56():102794. PubMed ID: 32454407 [TBL] [Abstract][Full Text] [Related]
3. A heterodimer formed by bone morphogenetic protein 9 (BMP9) and BMP10 provides most BMP biological activity in plasma. Tillet E; Ouarné M; Desroches-Castan A; Mallet C; Subileau M; Didier R; Lioutsko A; Belthier G; Feige JJ; Bailly S J Biol Chem; 2018 Jul; 293(28):10963-10974. PubMed ID: 29789425 [TBL] [Abstract][Full Text] [Related]
4. Homozygous GDF2 nonsense mutations result in a loss of circulating BMP9 and BMP10 and are associated with either PAH or an "HHT-like" syndrome in children. Hodgson J; Ruiz-Llorente L; McDonald J; Quarrell O; Ugonna K; Bentham J; Mason R; Martin J; Moore D; Bergstrom K; Bayrak-Toydemir P; Wooderchak-Donahue W; Morrell NW; Condliffe R; Bernabeu C; Upton PD Mol Genet Genomic Med; 2021 Dec; 9(12):e1685. PubMed ID: 33834622 [TBL] [Abstract][Full Text] [Related]
6. Regulation of the ALK1 ligands, BMP9 and BMP10. Li W; Salmon RM; Jiang H; Morrell NW Biochem Soc Trans; 2016 Aug; 44(4):1135-41. PubMed ID: 27528761 [TBL] [Abstract][Full Text] [Related]
7. The hepatic apelin system: a new therapeutic target for liver disease. Principe A; Melgar-Lesmes P; Fernández-Varo G; del Arbol LR; Ros J; Morales-Ruiz M; Bernardi M; Arroyo V; Jiménez W Hepatology; 2008 Oct; 48(4):1193-201. PubMed ID: 18816630 [TBL] [Abstract][Full Text] [Related]
8. Bone morphogenetic protein 9 (BMP9) and BMP10 enhance tumor necrosis factor-α-induced monocyte recruitment to the vascular endothelium mainly via activin receptor-like kinase 2. Mitrofan CG; Appleby SL; Nash GB; Mallat Z; Chilvers ER; Upton PD; Morrell NW J Biol Chem; 2017 Aug; 292(33):13714-13726. PubMed ID: 28646109 [TBL] [Abstract][Full Text] [Related]
9. Endothelial protective factors BMP9 and BMP10 inhibit CCL2 release by human vascular endothelial cells. Upton PD; Park JES; De Souza PM; Davies RJ; Griffiths MJD; Wort SJ; Morrell NW J Cell Sci; 2020 Jul; 133(14):. PubMed ID: 32576665 [TBL] [Abstract][Full Text] [Related]
10. Potential roles of BMP9 in liver fibrosis. Bi J; Ge S Int J Mol Sci; 2014 Nov; 15(11):20656-67. PubMed ID: 25393508 [TBL] [Abstract][Full Text] [Related]
11. Emerging role of adipokine apelin in hepatic remodelling and initiation of carcinogensis in chronic hepatitis C patients. Farid RM; Abu-Zeid RM; El-Tawil A Int J Clin Exp Pathol; 2014; 7(5):2707-17. PubMed ID: 24966992 [TBL] [Abstract][Full Text] [Related]
12. Different cardiovascular and pulmonary phenotypes for single- and double-knock-out mice deficient in BMP9 and BMP10. Bouvard C; Tu L; Rossi M; Desroches-Castan A; Berrebeh N; Helfer E; Roelants C; Liu H; Ouarné M; Chaumontel N; Mallet C; Battail C; Bikfalvi A; Humbert M; Savale L; Daubon T; Perret P; Tillet E; Guignabert C; Bailly S Cardiovasc Res; 2022 Jun; 118(7):1805-1820. PubMed ID: 34086873 [TBL] [Abstract][Full Text] [Related]
13. In Search of "Hepatic Factor": Lack of Evidence for ALK1 Ligands BMP9 and BMP10. Capasso TL; Trucco SM; Hindes M; Schwartze T; Bloch JL; Kreutzer J; Cook SC; Hinck CS; Treggiari D; Feingold B; Hinck AP; Roman BL Am J Respir Crit Care Med; 2021 Jan; 203(2):249-251. PubMed ID: 32871084 [No Abstract] [Full Text] [Related]
14. Bone Morphogenetic Protein 9 Is a Paracrine Factor Controlling Liver Sinusoidal Endothelial Cell Fenestration and Protecting Against Hepatic Fibrosis. Desroches-Castan A; Tillet E; Ricard N; Ouarné M; Mallet C; Belmudes L; Couté Y; Boillot O; Scoazec JY; Bailly S; Feige JJ Hepatology; 2019 Oct; 70(4):1392-1408. PubMed ID: 30964206 [TBL] [Abstract][Full Text] [Related]
15. Molecular basis of ALK1-mediated signalling by BMP9/BMP10 and their prodomain-bound forms. Salmon RM; Guo J; Wood JH; Tong Z; Beech JS; Lawera A; Yu M; Grainger DJ; Reckless J; Morrell NW; Li W Nat Commun; 2020 Apr; 11(1):1621. PubMed ID: 32238803 [TBL] [Abstract][Full Text] [Related]
16. Clinical Implications of the Serum Apelin Level on Portal Hypertension and Prognosis of Liver Cirrhosis. Lim YL; Choi E; Jang YO; Cho YZ; Kang YS; Baik SK; Kwon SO; Kim MY Gut Liver; 2016 Jan; 10(1):109-16. PubMed ID: 25963087 [TBL] [Abstract][Full Text] [Related]
17. Targeting secreted cytokine BMP9 gates the attenuation of hepatic fibrosis. Li P; Li Y; Zhu L; Yang Z; He J; Wang L; Shang Q; Pan H; Wang H; Ma X; Li B; Fan X; Ge S; Jia R; Zhang H Biochim Biophys Acta Mol Basis Dis; 2018 Mar; 1864(3):709-720. PubMed ID: 29223735 [TBL] [Abstract][Full Text] [Related]